Loading
A phase 3 trial of Ramucirumab, Erlotinib, Gefitinib in non-small-cell lung cancer and small-cell lung cancer, run by Eli Lilly and Company, active and no longer recruiting.
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) is a phase 3 interventional study registered as NCT02411448 by Eli Lilly and Company, with 545 participants enrolled, started 2015-05-06 and due to reach its primary completion in 2019-01-23. Interventions recorded: Ramucirumab, Placebo, Erlotinib, Gefitinib, Osimertinib. Conditions listed: Metastatic Non-Small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2020; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
545 enrolled.
95% CI 15.4 to 21.6; Figures from the ClinicalTrials.gov results section (first posted 2020-03-04), not from a publication · 95% CI 11.0 to 13.5
Source95% CI 70.8 to 81.9; Figures from the ClinicalTrials.gov results section (first posted 2020-03-04), not from a publication · 95% CI 69.0 to 80.3
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Part B: Progression Free Survival (PFS)primary | Part B: Ramucirumab+ Erlotinib | 224 | 19.4 months | 0.591 (0.461 to 0.76) | <0.0001 | link |
| Part B: Placebo+ Erlotinib | 225 | 12.4 months | ||||
| Part B: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) | Part B: Ramucirumab+ Erlotinib | 224 | 76.3% | - | 0.7413 | link |
| Part B: Placebo+ Erlotinib | 225 | 74.7% |
A second publication from the RELAY trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
This is the paper Europe PMC returns for registry id NCT02411448 with the most citations, so it is the natural first reading for anyone following the RELAY trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
Shares Erlotinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Erlotinib, Eli Lilly (incl. Loxo), Small-cell lung cancer, Small-molecule kinase inhibitors.